One hypothesis of the cycle of anhedonia (loss of interest or pleasure) in patients with depression is illustrated in this image; this hypothesis comes from a series of experiments performed on a sample of psychology students.1 The students were given the Beck Depression Inventory (BDI), and only those who displayed either high (BDI score >20) or low (<10) depressive symptomatology were included in the study.1 As well as completing a series of questionnaires, their helping behaviour was tested during the debriefing process when, in what was made to seem like an accident, a researcher dropped a pile of papers near the participant – latency to help, and the degree of help provided was used as a proxy for helping behaviour, and social anhedonia.1 Higher levels of participants not helping were seen in the high depressive symptomatology group.1

There have been attempts to assay the effectiveness of newer antidepressants against the symptoms of anhedonia; one such study found that treatment over eight weeks with a melatonin receptor agonist decreased severity scores on depression scales, as well as scores on the Snaith-Hamilton Pleasure Scale that measures anhedonia.3 However, effectiveness on symptoms of anhedonia remains an unmet need in the treatment of MDD.1,2,3

MDD=major depressive disorder

file_download Download in HQ

Related content

description Article
Treatment-Resistant Depression (TRD) – definition, clinical manifestation, and evidence-based treatment

Treatment-resistant depression (TRD) represents a significant clinical challenge, affecting approximately 30% of individuals with major depressive disorder (MDD) who fail to respond to at least two adequate antidepressant trials.

25.09.2025 Depression
image Image Diagram titled 'Sequential Treatment Optimization Scheme for MDD' showing patient improvement over treatment time across four stages. Stage 1 includes monotherapy, dose optimization, and rTMS; Stage 2 includes augmentation, combination antidepressant, add-on treatment, rTMS/ECT; Stage 3 includes add-on psychopharmacotherapy, switch to tranylcypromine, rTMS/TBS/ECT/VNS; Stage 4 includes repetition or experimental psychopharmacotherapy/brain stimulation. Curved lines represent different patient trajectories, with horizontal dotted lines indicating thresholds for response and remission. Some lines show improvement, while others show little or worsening response over time.
Sequental Treatment Optimization Scheme for Major Depressive Disorder

Sequential treatment optimization scheme for major depressive disorder generated according to international evidence.

18.09.2025 Depression
image Image Infographic titled 'Identification and Effective Management of Factors Potentially Confounding Treatment Response'. It shows eight stacked boxes listing key steps: Check dose and duration of the current antidepressant trial Explore and reduce side effects Consider and treat comorbidities Consider and reduce ongoing stressors Evaluate treatment adherence Pharmacogenomic testing (CYP450) Check and avoid unfavorable medical interaction Evaluate initial therapies and follow recommended treatment algorithm. At the bottom, references are cited (Dold & Kasper, 2017; Kraus et al., 2019), and the image is credited to Neurotorium."
Identification and Effective Management of Factors Potentially Confounding Treatment Response

Key steps for managing factors that may confound antidepressant treatment response, including dose, side effects, comorbidities, stressors, adherence, pharmacogenomics, interactions, and treatment algorithms.

18.09.2025 Depression